0001231919-20-000018.txt : 20200330 0001231919-20-000018.hdr.sgml : 20200330 20200330141121 ACCESSION NUMBER: 0001231919-20-000018 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200330 DATE AS OF CHANGE: 20200330 EFFECTIVENESS DATE: 20200330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xalud Therapeutics, Inc. CENTRAL INDEX KEY: 0001646982 IRS NUMBER: 270422708 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-363916 FILM NUMBER: 20756037 BUSINESS ADDRESS: STREET 1: 200 GARRETT STREET STREET 2: SUITE S CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 BUSINESS PHONE: 434-980-8105 MAIL ADDRESS: STREET 1: 200 GARRETT STREET STREET 2: SUITE S CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 D 1 primary_doc.xml X0708 D LIVE 0001646982 Xalud Therapeutics, Inc. 2120 UNIVERSITY AVENUE SUITE 532 BERKELEY CA CALIFORNIA 94704 434-980-8105 DELAWARE None None Corporation true Stephen Collins c/o Xalud Therapeutics, Inc. 2120 University Avenue, Suite 532 Berkeley CA CALIFORNIA 94704 Executive Officer Director Sean Stalfort c/o Xalud Therapeutics, Inc. 2120 University Avenue, Suite 532 Berkeley CA CALIFORNIA 94704 Director Jayson Rieger c/o Xalud Therapeutics, Inc. 2120 University Avenue, Suite 532 Berkeley CA CALIFORNIA 94704 Director Paul B. Manning c/o Xalud Therapeutics, Inc. 2120 University Avenue, Suite 532 Berkeley CA CALIFORNIA 94704 Director Biotechnology Decline to Disclose 06b false 2020-03-06 false true false 0 25150000 5000000 20150000 false 1 0 0 0 false Xalud Therapeutics, Inc. /s/Stephen Collins Stephen Collins Executive Chairman 2020-03-30